{"paper_id":"c08254bb-02b6-4e02-984b-5eba71f2abc9","body_text":"Abstract\nPurpose\nTo compare the prognoses of women with high-grade ovarian carcinoma arising in endometriosis (OCAE) to those of women with ovarian high-grade serous carcinoma (HGSC)\nMaterial and Methods\nThis multicenter, retrospective, case–control study included patients with OCAE at two gynecologic oncology centers in Turkey between January 2006 and December 2016. Of a total of 202 women with a diagnosis of OCAE, 70 women with high-grade OCAE were included. Each case high-grade OCAE was attributed to two women with ovarian HGSC. Survival analysis was performed using the Kaplan–Meier method.\nResults\nEleven patients with high-grade OCAE had recurrent disease (15.7%) when compared to 47 patients (33.6%) with HGSC (p = 0.008). The 5-year disease-free survival (DFS) rate of the patients having high-grade OCAE was significantly higher than the women with HGSC (78.3% vs. 56.2%; p = 0.007, respectively). According to the 5-year overall survival (OS) rates, there was no significant difference between high-grade OCAE and HGSC (79.5% vs. 70.1%; p = 0.210, respectively).\nConclusion\nAlthough this retrospective study demonstrated a significant decrease in recurrence rate and an increase in the 5-year DFS rate in patients with high-grade OCAE, OS rates of the patients with HGSC and high-grade OCAE seem to be similar.\nSimilar content being viewed by others\nReferences\nGrandi G, Toss A, Cortesi L et al. The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life. Biomed Res Int 2015:751571. https://doi.org/10.1155/2015/751571.\nPearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385–94. https://doi.org/10.1016/S1470-2045(11)70404-1.\nKobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29(3):203–11. https://doi.org/10.1097/PGP.0b013e3181c042b6.\nCho KR, Shih IM. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313. https://doi.org/10.1146/annurev.pathol.4.110807.092246.\nHannibal CG, Vang R, Junge J, et al. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978–2006. Gynecol Oncol. 2012;125(3):655–60. https://doi.org/10.1016/j.ygyno.2012.02.028.\nZwart J, Geisler JP, Geisler HE. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma. Eur J Gynaecol Oncol. 1998;19(3):225–8.\nMiyamoto M, Takano M, Goto T, et al. Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review. J Gynecol Oncol. 2013;24(1):37–43. https://doi.org/10.3802/jgo.2013.24.1.37.\nErzen M, Rakar S, Klancnik B, et al. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol. 2001;83(1):100–8. https://doi.org/10.1006/gyno.2001.6382.\nSteed H, Chapman W, Laframboise S. Endometriosis-associated ovarian cancer: a clinicopathologic review. J Obstet Gynaecol Can. 2004;26(8):709–15.\nOrezzoli JP, Russell AH, Oliva E, et al. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol. 2008;110(3):336–44. https://doi.org/10.1016/j.ygyno.2008.05.025.\nKumar S, Munkarah A, Arabi H et al. Prognostic analysis of ovarian cancer associated with endometriosis. Am J Obstet Gynecol 2011;204(1):63.e61–7. https://doi.org/10.1016/j.ajog.2010.08.017.\nWang S, Qiu L, Lang JH et al. Clinical analysis of ovarian epithelial carcinoma with coexisting pelvic endometriosis. Am J Obstet Gynecol 2013;20(5):413.e1–5. https://doi.org/10.1016/j.ajog.2012.12.004.\nDavis M, Rauh-Hain JA, Andrade C, et al. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol. 2014;132(3):760–6. https://doi.org/10.1016/j.ygyno.2014.01.012.\nTan DS, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol. 2007;60(4):355–60. https://doi.org/10.1136/jcp.2006.040030.\nTothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198–208. https://doi.org/10.1158/1078-0432.CCR-08-0196.\nPrat J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124(1):1–5. https://doi.org/10.1016/j.ijgo.2013.10.001.\nSahin H, Sari ME, Cuylan ZF, et al. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma? Arch Gynecol Obstet. 2018;297(4):1005–13. https://doi.org/10.1007/s00404-018-4651-6.\nBamias A, Sotiropoulou M, Zagouri F, et al. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. Eur J Cancer. 2012;48(10):1476–83. https://doi.org/10.1016/j.ejca.2011.09.023.\nBouchard-Fortier G, Panzarella T, Rosen B, et al. Endometrioid Carcinoma of the Ovary: Outcomes Compared to Serous Carcinoma After 10 Years of Follow-Up. J Obstet Gynaecol Can. 2017;39(1):34–41. https://doi.org/10.1016/j.jogc.2016.10.006.\nKim HS, Kim TH, Chung HH, et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer. 2014;110(7):1878–90. https://doi.org/10.1038/bjc.2014.29.\nYe S, Yang J, You Y, et al. Comparative study of ovarian clear cell carcinoma with and without endometriosis in People’s Republic of China. Fertil Steril. 2014;102(6):1656–62. https://doi.org/10.1016/j.fertnstert.2014.08.008.\nPark JY, Kim DY, Suh DS, et al. Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma. Int J Gynecol Cancer. 2018;28(1):11–8. https://doi.org/10.1097/IGC.0000000000001136.\nPaik ES, Kim TJ, Choi CH, et al. Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. J Gynecol Oncol. 2018;29(2): e18. https://doi.org/10.3802/jgo.2018.29.e18.\nLu J, Tao X, Zhou J, et al. Improved clinical outcomes of patients with ovarian carcinoma arising in endometriosis. Oncotarget. 2017;8(4):5843–52. https://doi.org/10.18632/oncotarget.13967.\nR Barakat AB, M Markman, ME Randall. Principles and Practice of Gynecologic Oncology. 2013. Lippincott Williams & Wilkins.\nNCCN Ovarian Cancer (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed 25 Mar 2019.\nColombo N, Sessa C, Bois AD, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672–705. https://doi.org/10.1093/annonc/mdz062.\nFunding\nThis research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.\nAuthor information\nAuthors and Affiliations\nContributions\nI. Y., H. C., M. M. M., A. A. performed surgical and medical practices; I. Y., M. M. M., A. A. provided the concept; H. C., M. M. M., A. A. designed the study; I. Y., H. S., M. E. S. were involved in data collection or processing; A. N. H., E. A. S., H. C., M. M. M. contributed to analysis or interpretation; M. E. S., A. N. H., E. A. S performed literature search; I. Y., M. M. M. wrote the article.\nCorresponding author\nEthics declarations\nConflict of interest\nThe authors declare that they have no conflict of interest.\nEthics Approval\nThis retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Institutional review board approved retrospective analysis of the Cancer Registry database (Approval date: Feb 12th 2018 Approval number: 23).\nInformed consent\nInformed consent was obtained from all individual participants included in the study.\nConsent to publish\nPatients signed informed consent regarding publishing their data.\nAvailability of data\nAll data and materials support their published claims and comply with field standards.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nAbout this article\nCite this article\nYalcin, I., Sahin, H., Sari, M.E. et al. Clinical Outcomes of Patients with High-Grade Ovarian Carcinoma Arising in Endometriosis Compared to Ovarian High-Grade Serous Carcinoma. Indian J Gynecol Oncolog 19, 58 (2021). https://doi.org/10.1007/s40944-021-00559-z\nReceived:\nRevised:\nAccepted:\nPublished:\nVersion of record:\nDOI: https://doi.org/10.1007/s40944-021-00559-z","source_license":"CC0","license_restricted":false}